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In Brief
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https://doi.org/10.1016/j.ccell.2018.07.001SUMMARYOur comprehensive analysis of alternative splicing across 32 The Cancer Genome Atlas cancer types from
8,705 patients detects alternative splicing events and tumor variants by reanalyzing RNA and whole-exome
sequencing data. Tumors have up to 30%more alternative splicing events than normal samples. Association
analysis of somatic variants with alternative splicing events confirmed known trans associationswith variants
in SF3B1 and U2AF1 and identified additional trans-acting variants (e.g., TADA1, PPP2R1A). Many tumors
have thousands of alternative splicing events not detectable in normal samples; on average, we identified
z930 exon-exon junctions (‘‘neojunctions’’) in tumors not typically found in GTEx normals. From
Clinical Proteomic Tumor Analysis Consortium data available for breast and ovarian tumor samples, we
confirmed z1.7 neojunction- and z0.6 single nucleotide variant-derived peptides per tumor sample that
are also predicted major histocompatibility complex-I binders (‘‘putative neoantigens’’).INTRODUCTION
Analyses of cancer genomes have predominantly focused on the
evaluation of somatic non-synonymous protein-altering muta-
tions and the potentially pathogenic impact such mutationsSignificance
Immunotherapy is currently a promising direction for treating c
approach. Among those that show potential benefit from immu
geted vaccine is a considerable challenge. Tumor-specific splic
tial neoantigens that may affect the immune response and coul
vaccines. By considering neojunction-derived, in addition to S
samples for which at least one putative neoantigen can be ide
creases from 30% to 75%.
Cancer Cell 34, 211–224, A
This is an open access article under the CC BY-Nhave on gene expression, protein function, and downstream
pathways (Futreal et al., 2001; Greenman et al., 2007). The types
of samples collected and the data generated by The Cancer
Genome Atlas (TCGA) have been specifically chosen to support
such analyses (Cancer Genome Atlas Research Network, 2008).ancer patients. Not all cancer types are suited for this type of
notherapeutic treatment, deriving suitable antigens for a tar-
ing presents a large new class of splicing-associated poten-
d be exploited in immunotherapy; e.g., in personalized tumor
NV-derived, peptides as potential antigens, the fraction of
ntified and confirmed by mass spectrometry proteomics in-
ugust 13, 2018 ª 2018 The Authors. Published by Elsevier Inc. 211
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
However, the developed resources also provide an excellent op-
portunity for an in-depth analysis of the changes of the transcrip-
tome in tumors, which has received much less attention so far.
Individual changes in regulatory binding sites or alterations to
the protein coding sequences can have a strong functional
impact, leading to selective growth advantages for tumor cells.
Several cases have been reported where the physiological
outcome of such alterations comes into functional effect through
the alteration of splicing. A prominent example for cis-acting
mutations is found in the splice junctions ofMET leading to skip-
ping of exon 14, resulting in activation of MET but also providing
specific sensitivity to MET inhibitors (Frampton et al., 2015; Paik
et al., 2015). In addition, trans-acting alterations have been
described where a somatic variant in a splicing factor leads to
many splicing changes across the genome. For instance, so-
matic alterations of the splicing factor U2AF1 lead to a widely
altered landscape of splicing events in certain cancer types,
such as lung adenocarcinomas (Brooks et al., 2014) or myelo-
dysplastic syndromes (Graubert et al., 2012). Another well-char-
acterized set of alterations are changes of the splicing factor
SF3B1, which have been linked to changes in splicing patterns
in various tumor types, such as uveal melanoma (Furney et al.,
2013) or lymphocytic leukemia (Rossi et al., 2011), and are
suggested to promote aberrant splicing patterns via alternative
branchpoint usage (Alsafadi et al., 2016). More recently, the
analysis of alternative splicing has also been shown to be of
prognostic value for multiple cancer types, including non-small
cell lung cancer (Li et al., 2017), ovarian cancer (Zhu et al.,
2017), breast cancer (Bjørklund et al., 2017), uveal melanoma
(Robertson et al., 2017), and glioblastoma (Marcelino Meliso
et al., 2017).
RESULTS
Workflow for Integrated Pan-Cancer Analysis
We devised a versatile and comprehensive workflow to integrate
analyses of RNA and whole-exome sequencing data from tu-
mors from 8,705 donors, including 670 matched normal sam-
ples, spanning a range of 32 cancer types (Figure 1 left, middle).
The main questions answered by the developed methodology
are (1) the identification of underlying genetic changes leading
to splicing variability in tumors (Figure 1 right top), (2) a compre-
hensive analysis of quantitative and qualitative changes of
alternative splicing in tumors (Figure 1 right middle), and (3)
determining the extent to which splicing aberrations can be ex-
ploited for immunotherapy (right bottom).
Landscape of Alternative Splicing Events in Cancer
Based on recently developed methodology to construct individ-
ual splicing graphs for large gene sets (Kahles et al., 2016), we
have systematically quantified changes in splicing event usage
across the full TCGA cohort. Throughout all cancer types we
found a substantial number of high-confidence splicing events,
confirmed by at least 20 RNA sequencing (RNA-seq) reads (Dje-
bali et al., 2012; Nellore et al., 2016; Wang et al., 2008), that
contain introns not annotated in GENCODE (Figures 2A, S1A,
and S1B), increasing the total number of observed events at
least 2-fold. Despite accounting for cohort size and read length
effects, we still observed a high variability of additional splicing212 Cancer Cell 34, 211–224, August 13, 2018across individual cancer types. Compared with the alternative
splicing events in the GENCODE annotation, we observed that
exon skip and alternative 30 site events represent the majority
(27.1% and 27.5%, respectively) of the non-annotated events
(Figures S1C and S1D).
When directly contrasted to matching normal tissue, we found
a larger amount of alternative splicing events in tumor samples
than in normal samples for the majority of the investigated
cancers (Figures 2B and S1E–S1H; sample size of tumor and
normal samples is 40 for all sets). This difference is especially
pronounced for lung adenocarcinoma (LUAD), where we
observed an over 30% increase in exon skip events in tumor
samples. This effect became even stronger when only events
with the strongest splicing changes (measured as an increased
DPSI [percent spliced in]; Schafer et al., 2015) were used (Fig-
ures S1I and S1J).
We have visualized the splicing diversity across the full cohort
utilizing a standard dimensionality reduction technique (t-distrib-
uted stochastic neighbor embedding [t-SNE]; Van der Maaten
and Hinton, 2008; Figures 2C and S1K–S1N) highlighting both
the tissue-specific nature of alternative splicing but also can-
cer-type-specific differences and commonalities. We observed
that cancer types, such as colon adenocarcinoma (COAD) and
rectum adenocarcinoma (READ) or the group of squamous cell
cancers, including lung squamous cell carcinoma (LUSC),
cervical squamous cell carcinoma (CESC), and head and neck
squamous cell carcinoma (HNSC), that are commonly ascribed
with similar characteristics (Cancer Genome Atlas Network,
2012; Hoadley et al., 2014) clustered closely together, even over-
powering the identity of the tissue of origin. Examples of the latter
are LUAD and LUSC. The same pattern was observed based on
a clustering of themedian splicing profile (Figures S1O and S1P).
Here, we also observed a cluster of uterine carcinosarcoma,
uveal melanoma, mesothelioma, skin cutaneous melanoma,
and sarcoma, which was less pronounced in a similar clustering
based on gene expression profiles (Figures S1Q and S1R). Simi-
larly, kidney chromophobe cancers (KICH) are clearly separated
from kidney renal papillary cell carcinomas and kidney renal
clear cell carcinomas in the t-SNE based on splicing profile as
well as in the corresponding clustering (Figures S1K–S1N). We
did not observe similarities in exon skip splicing patterns be-
tween breast basal-like and serous ovarian cancers as reported
previously based on gene expression (Cancer Genome Atlas
Network, 2012), suggesting that gene expression profiles did
not drive the patterns in the same way as observed with alterna-
tive splicing. However, several breast basal-like cancers were
located in the cluster of squamous cell cancers, including sam-
ples of LUSC, which had previously been reported as similar to
basal-like breast cancer based on the analysis of transcriptional
similarities (Chung et al., 2002). Interestingly, we found that, in
breast cancer patients (BRCA), different cancer subtypes can
be distinguished based on exon skip splicing features (Figures
2D and S1L), forming a notable trajectory across the four main
subtypes with the luminal subtypes closely connected and the
basal subtype clearly separated. For tumor-matched normal
samples we found that, in almost all cases, they cluster clearly
separated from the corresponding tumors (Figure S1M). With re-
gard to possible confounding factors, such as library size, we did
not observe clear associations to the clustering (Figure S1N).
TCGA data Preprocessing Analyses
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Figure 1. Project Overview
Flow diagram of data and analyses presented in this work. The left schema represents approximate body source sites for the samples of the 32 analyzed cancer
types. Bar charts describe numbers of tumor and matched normal samples for each cancer. The numbers for tumor samples represent cases where both tumor
RNA-seq as well as whole-exome sequencing (WXS) data are available. The numbers for normal represent matched normal RNA-seq. All samples underwent
uniform preprocessing (middle, top), including sequence alignment, expression quantification, and alternative splicing analysis (middle, RNA). Furthermore,
samples were used for tumor variant calling and somatic variant calling by the Multi-Center Variant Call (MC3) project (center). In addition, data from other
sources, such as the GTEx project, the Broad Firebrowse, and Clinical Proteomic Tumor Analysis Consortium (CPTAC) were included (middle bottom). Different
data types were then combined into four integrative analysis sections. For the identification of splicing quantitative trait loci (sQTL, right, top), we associated
RNA-seq-derived splicing quantifications with WXS-derived genetic variants, to identify cis and trans effects. To highlight quantitative splicing differences be-
tween tumor and normal samples, we used the splicing quantifications to test for significant differences between tumor and normal (illustratedwith ***) and ranked
the results across all cancers (right, second). To discover neojunctions only present in cancer samples but unobserved in normals or a tissue-matched outgroup,
we integrated TCGA RNA-seq data and GTEx RNA-seq data to determine the degree of splicing aberration per sample, marking stark splicing outliers (right,
third). Lastly, we analyzed the neojunctions and tested the extent they are translated into proteins, utilizing CPTAC data, confirming a large number of peptides.
Many confirmed peptides were also predicted to be MHC-I binders and are excellent neoantigen candidates, promising for immunotherapy (right, bottom). See
also Figures S1–S5.These observations were less pronounced for gene expression
counts (Figures S1S and S1T).
Somatic trans Associations Drive Changes of Splicing
Events
We performed an association study linking somatic single nucle-
otide variant (SNV) positions with alternative splicing changes in
up to 8,255 donors. As phenotypes we considered a total of
94,749 exon skipping, 30,755 alternative 50, and 48,365 alterna-
tive 30 events. We considered recurrently called tumor sample
population-level variant calls. For the pan-cancer association
study we used a linear mixed model implemented in LIMIX (Lip-
pert et al., 2014), correcting for population, tissue, and batch ef-
fects. We also checked trans-splicing quantitative trait loci
(sQTL) for a potential bias toward purity and ploidy as well as apotential bias for patient gender and total mutational load (Fig-
ure S2A). We found that mutational load oftentimes strongly
correlates with the genotype of individual variants (Figures
S2B–S2D) and those variants also showed significant correlation
among each other. This finding makes it difficult to determine
whether individual variants themselves affect splicing event
changes or are rather tagging higher mutational load, which in
turn may have an effect on a wide range of splicing events. For
this reason, we have excluded variants showing evidence of
association with mutational burden (nominal p value <0.01)
from further analysis. A subset of variants, including variants in
SF3B1 and U2AF1, did not show this pattern (Figure S2E). In a
joint analysis of cis and trans associations with 50% prior on
each type, we identified 32 cis- and seven trans-sQTL (Bonfer-
roni corrected p < 0.05).Cancer Cell 34, 211–224, August 13, 2018 213
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Figure 2. Detection of Tumor Alternative Splicing and Splicing Landscape
(A) Detection of alternative splicing events. For each cancer type, we considered 40 randomly chosen samples and jointly identified alternative splicing events
(exon skipping events are shown) containing junctions that each can be confirmed with a minimum (min) of 20 spliced reads in at least one sample for the
respective cancer type. The darker bar fractions correspond to known alternative splicing events and the lighter bar fractions to additional events that are not part
of the GENCODE (v19) annotation.
(B) Comparison of the number of alternative splicing events on 40 matched tumor (T) and normal sample (N) pairs for TCGA cancer types with at least 40 normal
samples, for events containing junctions confirmed with at least five reads (top) or 20 reads (bottom) in the respective cancer type.
(C) Landscape of alternative splicing for all considered TCGA samples computed on exon skipping PSI scores only. Each point represents a sample, colored ac-
cording to its TCGA project code. The position of each sample is computed as a t-distributed stochastic neighbor embedding (t-SNE) representation of the higher-
dimensional splice event PSI matrix. Tumor samples are shown as circles and normal samples as triangles. The dashed box represents an area detailed in (D).
(D) Samples in the splicing landscape highlighted for subtypes of BRCA. Normal samples are shown as triangles and tumor samples as circles colored according
to subtype. Samples of all other cancer types are shown in gray.The trans-sQTL genes included variants with known effect on
splicing in SF3B1 (Alsafadi et al., 2016) (Figure 3A and 3B) and
U2AF1 (Brooks et al., 2014) but also several candidates whose
effects on splicing are less established. One such example is
TADA1, where we observe that the distribution of splice event
targets across the alternative event types shows a similar 30
alternative splicing bias as the targets of the SF3B1 mutations
(Figure 3C). TADA1 interacts with SF3B5, which itself interacts
with various other splicing factors (including SF3B1) and
suggests a possible mechanism (Figure 3D). We also found
that mutations in the cancer driver gene PPP2R1A are associ-
ated with alternative splicing changes in SCRIB, which itself is
a tumor suppressor gene and suggests a mechanism on how
PPP2R1A may be driving tumorigenesis (Sayani et al., 2008). A
further example is IDH1, where the same recurrent somatic214 Cancer Cell 34, 211–224, August 13, 2018missense variant had been associated with inhibiting the enzy-
matic functions of histones and demethylases. IDH1 variants
have been shown to be most prevalent in brain lower grade
glioma (LGG) and glioblastoma multiforme (GBM), which we
also observe in the Pan-Cancer Atlas cohort (Figure S2F) (Yan
et al., 2009). They often appear in patients with low-grade
gliomas and have been associated with more favorable out-
comes (Yen et al., 2010). Due to the prevalence pattern of
IDH1 variants, we also tested for association within the glioma,
glioblastoma, and pheochromocytoma and paraganglioma
(GBM/LGG/PCPG) cohort to exclude the possibility of tissue-
specific effects. In total, we observed broad splicing changes
across 377 events (Figure 3B), which are also observed in 326
(243 for LGG only) events (Spearman correlation, Bonferroni cor-
rected p value <0.05) within the GBM/LGG/PCPG cohort,
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Figure 3. Large-Scale Somatic cis- and trans-sQTL Analysis
(A) Two-dimensional Manhattan plot with location of a variant (x axis) associated (p% 0.05 after Bonferroni correction separately for cis and trans associations)
with an alternative splicing event at a separate location (y axis). Points along the diagonal correspond to cis associations (window 1Mb) and the remaining points
correspond to trans associations. The marginal bar plots show the number of splicing events found to be associated with a single variant (top) and the number of
associations found for each alternative splicing event (right). The colored points indicate whether an alternative splicing event or sQTL is within an RNA binding
gene (green), cancer census gene (blue), or cell cycle gene (orange). The pie charts on top of the bar show the breakdown of splicing event type composition of the
sQTL targets. Brown indicates alternative 30 events, gray alternative 50 events, and green exon skip events.
(B) Heatmaps of selected trans-sQTL: PSI z scores of alternative splicing events (columns) significantly associated in trans with the variant. The color bar on the
left shows the mutation status for each sample (rows). For visualization purposes, the heatmaps are downsampled to highlight the differences.
(C) Pie charts from (A) detailing the distribution of splicing event targets across three categories (alternative 50, alternative 30, and exon skip events).
(D) Protein-protein interaction network of TADA1 and some selected partners (e.g., SF3B5).
See also Figure S2.excluding the possibility that this association was mainly driven
by tissue identity. Here, we report a link between IDH1 variant
and splicing, which is noteworthy since the importance of tu-
mor-specific alternative splicing has already been established
(Lefave et al., 2011; Venables et al., 2009).
Tumor-Specific Splicing Patterns
While significant differences in splicing between tumor and
normal samples have been described before (Sebestye´n et al.,
2015; Srebrow and Kornblihtt, 2006), our analysis strategyallowed us to draw a more complete picture of the splicing
landscape over a large array of different tumor types and sub-
types. Observations described in the previous sections have
shown that a large fraction of the identified events are either quite
rare in general or are observed across multiple cancer types but
remain rare within the individual tissue, which complicates
differential analysis. Also, tissue-specific splicing confounds
the assessment of significant differences between tumors and
normal samples across cancer types. Our strategy was therefore
2-fold: (1) uncovering rare splicing outliers in tumor samples thatCancer Cell 34, 211–224, August 13, 2018 215
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Figure 4. Differential and Outlier Splicing
(A) Strip plots showing outlier splicing for an exon skipping event inPTEN (top) and an alternative 30 splice site event inNDRG1 (bottom). Each column represents a
cancer type with its matched normal directly adjacent if available (left of dashed line) and GTEx normal samples (right of dashed line). Each dot corresponds to the
PSI value of the selected splicing events in one sample. Outlier samples are emphasized through increased marker size with black outline.
(B) Result of differential splicing analysis between tumor and matched normals for 14 cancer types. Rows correspond to the 40 most significantly altered genes
from the COSMIC cancer census set. Shading corresponds to log10(p value). Columns represent cancer types.
(legend continued on next page)
216 Cancer Cell 34, 211–224, August 13, 2018
recur over multiple cancer types (PSI value deviates strongly
from all other samples), and (2) differentially analyzing the
broader changes in splicing within the cancer types where tis-
sue-matched normal samples are available.
We identified a large set of 2,570 outlier events in 936 genes,
56 (6%) of which are included in the COSMIC (Catalogue of So-
matic Mutations in Cancer) cancer gene census list. One prom-
inent example is the tumor suppressor PTEN, which shows
recurrent skipping of exon 3 in multiple cancer types (Figure 4A
top) with a strong signal in COAD, LUSC, and uterine corpus
endometrial carcinoma (UCEC), not correlating with sample
size for the individual groups. Although alternative splicing of
PTEN in the context of cancer has been described before
(Agrawal and Eng, 2006; Okumura et al., 2011), the skipping of
exon 3 has so far been mostly linked to predisposition for herita-
ble disorders (Celebi et al., 2000; Chen et al., 2017). Another
example not well linked to splicing is the metastasis suppressor
gene NDRG1 (Kovacevic et al., 2011) (Figure 4A bottom).
Although in each cancer type only very few outlier samples exist
(with BRCA showing the strongest signal), a clear recurrence
was apparent with 14 of the 32 cancer types showing at least
one notable outlier. When comparing the splicing pattern with
an outgroup set of more than 3,000 normal samples for 31 tis-
sues from the GTEx study, we found none of the outliers to be
present (Figure 4A).
In addition to rare outliers, we also analyzed broader shifts in
splicing within the individual cancer types through a differential
analysis of splice form usage between tumor and normal
samples. We recovered a significant number of genes from the
cancer gene census set as recurrently differentially spliced
across tumor types (Figure 4B), partially showing pan-cancer
properties (TPM3 in BRCA, HNSC, READ, and lung cancers).
One of the genes we found most frequently differentially spliced
across all tumor types is PKM. While alternative splicing of exon
9 exclusion giving rise to a change from PKM into PKM2 has
been reported previously (Clower et al., 2010; David et al.,
2010), suggesting a role not only in the alteration of metabolic
function but also in tumor cell proliferation, we detect alternative
30 site usage for exon 2. Another gene worth highlighting in the
context of tumor-specific splicing is BCL2L1 (BCL-x), which
produces two splice forms with opposite functions via differen-
tial 50 splice site usage regulated byRBM4 expression, switching
between anti-apoptotic or pro-apoptotic states (Wang et al.,
2014). Among the top differentially spliced genes, we find a
significant enrichment of cancer census genes (5 out of 50,
p < 0.003, fold change 3.45, hypergeometric test). In addition,
we also observed differential splicing in numerous other factors
previously connected to cancer progression, such as NUMB,
which encodes a negative regulator of NOTCH and has been
previously linked to lung cancers (Pece et al., 2011). We found(C) Number of neojunctions per sample for 32 cancer types. Each dot represent
annotation and not (or only very rarely) in tissue-matched GTEx samples. If at le
indicated by a horizontal dotted red line. Cancer types are sorted from left to rig
(D) Overview of tumor introns exclusively detected in cancer samples but not in m
middle panel to TCGA matched normal samples, and the right panel to tissue-m
tumor-specific intron confirmedwith RNA-seq in the corresponding sample group
between tumor and matched normal samples. For multiple introns per gene, the
See also Figures S3 and S4.NUMB to be differentially spliced not only in lung cancers but
also in UCEC (Figure S3). In summary, the joint ranking of differ-
entially spliced genes provides a rich resource for the develop-
ment of new hypotheses.
Increased Complexity of Splicing in Cancer
In addition to the differential usage of splice forms, we were also
interested in the identification of exon-exon junctions (EEJs),
predominantly observable in tumor samples. We call such
tumor-specific EEJs ‘‘neojunctions’’. Over all samples of the
study, we identifyz251,000 such neojunctions, with an average
of 930 per sample (Figures 4C and S4A and S4B). Despite being
similar in sample size, LUAD and UCEC had generally higher
numbers of neojunctions than LUSC or prostate adenocarci-
noma. We found the strongest outliers in bladder urothelial
carcinoma (BLCA), UCEC, LUAD, BRCA, and COAD. We
observed amarked distinction between tumors and normal sam-
ples, where normal samples had substantially lower levels of
splicing burden than tumor samples (note that, according to
our definition, normal samples can also have neojunctions).
This difference appeared to vary across cancer types. Although
BLCA, CESC, LUSC, and LUAD showed a very strong distinc-
tion, other cancer types, such as liver hepatocellular carcinoma
or KICH, had no difference between tumor and normal samples.
Notably, on the other end of the spectrum, cholangiocarcinoma
seems to have an opposite pattern, with normal samples
showing a consistently higher number of neojunctions. Further,
different tumor types showed differences in their most extreme
complexity values, which cannot be explained by library size or
mutational load (Figures S4C and S4D).
To answer the question of which genes contribute most often
to the set of neojunctions that could potentially be used as diag-
nostic or therapeutic markers, we derived a neojunctions-based
ranking. Surprisingly, we observed EEJs that show RNA-seq
support in over 50% of samples of specific tumor types but
are virtually non-existent in TCGA normal samples or GTEx (Fig-
ure 4D). Further, we found a large degree of recurrence across
cancer types but also observed tissue-specific patterns.
There is a large degree of variation among the cancer types
with the largest numbers of neojunctions in BLCA, UCEC,
LUAD, BRCA, and COAD that we cannot easily attribute to
technical factors. We hypothesize that the large number of
neojunctions in some samples can be attributed to a partial
breakdown of the splicing machinery that may be the result of
somatic mutations or dysregulation of splicing-related factors.
In analogy to the term chromothripsis (Stephens et al., 2011),
we call this effect syndeo mechanism thripsis, or syndeothripsis.
We have identified 110 and 37 TCGA tumor samples with high
and very high degree of splicing aberration (Figures S4E and
S4F), respectively. The splicing burden in those samples goess the number of tumor-specific introns of a single sample not observed in the
ast five tumor-normal samples were available, the median of neojunctions is
ht by the mean number of neojunctions.
atched normals. The leftmost panel corresponds to TCGA tumor samples, the
atched GTEx samples. Shading indicates the fraction of samples that have a
. Rows are sorted according to a ranking that is the result of significance testing
most significant intron was chosen.
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far beyond what we observe in most normal samples and we
therefore suggest that they are affected by syndeothripsis.
Neojunctions Lead to Potential Neoepitopes
The direct oncogenic effects of tumor-specific alternative
splicing are only one of the many consequences splicing can
have in a cancer context.We saw evidence indicating that a large
fraction of the increased splicing diversity often seems to be a
passenger rather than being the driving effect; in particular, we
did not find an enrichment of neojunctions in the cancer census
gene set (in contrast to the enrichment for differential exon
usage). It is quite possible that the increased splicing complexity
is due to a lower accuracy, or more ‘‘noise’’ (Pickrell et al., 2010),
of splicing in cancer cells that may have a disrupted splicing
machinery, although we did not find a direct correspondence
between mutational load and detected junctions (Figure S4G).
However, this additional transcriptomic complexity can poten-
tially be used to inform cancer therapy. The classic argument
is that a fraction of somatic alterations specific to the tumor is
translated and can potentially lead to specific neoepitopes.
Following this argument, we studied whether a similar effect
can be observed for tumor-specific alternative splicing. This is
motivated by our prior observation that such events are at least
an order of magnitude more abundant than somatic variants.
We will denote tumor-specific peptides generated through
splicing and predicted to be major histocompatibility complex
(MHC)-I binders as alternative splicing-derived putative neoepi-
topes (ASNs).
Due to the limited availability of proteomics data for TCGA
samples, we have restricted the scope of this study to 63 donors
for BRCA and ovarian serous cystadenocarcinoma (OV). Based
on patient-specific splicing graphs, we derived all polypeptides
generated by an EEJ. This resulted in a median of 539,925
EEJ-spanning polypeptides per donor (Figure 5A and Table 1).
From these polypeptides, we extracted a list of candidate
ASNs based on a pipeline of Clinical Proteomic Tumor Analysis
Consortium (CPTAC) mass spectrometry (MS) data confirmation
(Mertins et al., 2016; Zhang et al., 2016) andMHC-I binding affin-
ity prediction (Andreatta and Nielsen, 2016) incorporating infor-
mation on the human leukocyte antigen (HLA) type of each donor
(Figure 5A). When considering only RNA-seq-confirmed EEJs,
this resulted in, on average, 1.7 ASNs from 1.2 EEJs for each
of the samples. For 43/63 (68%) of all considered samples we
identified at least one ASN that was CPTAC confirmed and
that was a predicted MHC-I binder (Figure 5B). If we do not
require RNA-seq confirmation of the specific EEJ in a sample,
the number of CPTAC-confirmed, MHC-I binding 9-mers in-
creases significantly (on average z11 9-mers from eight EEJs
per sample, Figure S5A). Generally, we expect the real number
of ASNs to be higher as it would also include 9-mers not span-
ning an EEJ but completely residing inside a newly included
exon or inside a retained intron (not counted in this analysis).
Furthermore, a recent study showed that junction-spanning pep-
tides resulting from alternative splicing are underrepresented in
protein MS datasets due to the cleavage specificity of trypsin
(Wang et al., 2017).
In order to compare ASNs with putative neoepitopes derived
from SNVs, following an analogous protocol, we generated a
list of all SNV-derived 9-mers that are observed in the respective218 Cancer Cell 34, 211–224, August 13, 2018tumor DNA, can be confirmed by CPTAC mass spectra, and are
predicted MHC-I binders. On average we find 0.6 SNV-derived
putative neoepitopes derived from 0.4 SNVs per sample. Overall,
we found at least one SNV-derived putative neoepitope for 19/63
(30%) of all considered samples. Compared with other studies,
these numbers appear relatively low. This can be explained by
our requirement of MS validation, which retains only about 1%
of otherwise viable peptides due to the low sensitivity of MS.
For both cancer types, we found more ASNs than putative
neoepitopes derived from SNVs (Figure 5B). Considering ASNs
in addition to SNV-derived putative neoepitopes significantly
increased the fraction for which at least one CPTAC-confirmed
putative neoepitope can be confirmed from 30% to 75%
(Figure 5B).
We used RNA-seq data to determine the expression of all
neojunctions as a proxy for neojunction-derived 9-mer expres-
sion. Similarly, we used the product of RNA-seq-based
expression estimates for an exon segment with an SNV and
the respective variant allele frequency as a proxy for SNV-
derived 9-mer peptide expression. For comparison, we also
provide average exon fragment RNA expression as a proxy for
overall 9-mer expression. The expression distribution for neo-
junctions is notably different from the SNV-derived and
overall 9-mer expression distribution. Generally, neojunction-
derived 9-mers show slightly lower expression than SNV-derived
9-mers (Figure 5C). CPTAC-confirmed SNV-derived putative
neoepitopes show a higher overall associated RNA expression
than ASNs, but there are fewer of them per sample.
Independent of the source of a neoepitope, potential thera-
peutic utility arises from recurrent observation across multiple
patients. SNVs are typically rare, and we did not observe any
recurring CPTAC-confirmed SNV-derived putative neoantigens.
However, we did find that 15 ASNs in our study are observed
across several samples within the same cancer type and five
ASNs recur in both cancer types (Figure S5B and Table S1).
DISCUSSION
Alternative splicing events have previously been shown to
contribute to cancer development and progression. Several
examples of such mechanisms are known, but only a few
comprehensive studies on transcript changes are available
(Climente-Gonza´lez et al., 2017) and a complete picture of alter-
native splicing complexity and its potential to generate neoanti-
gens is still missing.
In this work, we focus on five types of alternative splicing
events, namely intron retention, exon skipping, mutually exclu-
sive exons, and alternative 30 and alternative 50 splice site
changes (Cartegni et al., 2002; Hatje et al., 2017; Roy et al.,
2013; Wang et al., 2008). Our study builds on a previously pub-
lished tool (Kahles et al., 2016) and analyzes specific splicing
event types involving a small number of exons from RNA-seq
data without the need to know complete transcripts. This study
is a major contribution toward a comprehensive analysis of alter-
native splicing events across all suitable TCGA samples (another
study without focus on cancer was performed in Nellore et al.,
2016). Most previous studies considered isoform expression of
known transcripts. For instance, a recent study analyzed the
impact of isoform switches on gene function (Climente-Gonza´lez
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Figure 5. Alternative Splicing-derived Putative Neoepitopes (ASNs)
(A) Overview of the ASN detection and validation workflow. Starting from the personalized splicing graph including sample-specific germline and somatic SNVs
and the GENCODE genome annotations, polypeptides are generated across the junctions of all introns (including neojunctions). Expression of the resulting
polypeptides is validated using CPTACmass spectra. From the expressed polypeptides, 9-mer substrings spanning junctions are enumerated and filtered based
on their presence in a non-cancer background set. For the remaining 9-mers, MHC binding predictions (NetMHC) are obtained with respect to the individual’s
HLA-I type. Predicted MHC-I binders (percentile rank <2.0) are considered ASNs. The analysis is repeated for somatic SNV-derived 9-mer peptides for com-
parison.
(B) Comparison of the contribution of alternative splicing and SNVs to the CPTAC-confirmed putative neoepitope landscape by cancer type. Average number of
CPTAC-confirmed neojunction- and SNV-derived 9-mers per sample (left). Average number of CPTAC-confirmed alternative splicing and SNV sites generating
putative neoepitopes per sample (center). Sample fractions with at least one CPTAC-confirmed alternative splicing- or SNV-derived putative neoepitope (right).
‘‘UNION’’ corresponds to the combination of both variant types. ‘‘Total’’ refers to the combination of both cancer types. Only neojunctions RNA-expressed in the
respective sample or with a minimum RNA expression of 20 spliced reads in at least one of the samples are considered.
(C) Violin plot showing the RNA expression distribution over all expressed neojunction- and SNV-derived 9-mers as well as the overall 9-mer expression dis-
tribution. Expression of neojunctions is estimated using the library-size normalized read count confirming the neojunction. For SNV-derived peptides expression
is determined by multiplying normalized segment read coverage by the SNV somatic variant allele fraction, and for overall 9-mer expression normalized segment
read coverage of all 9-mers is used. The set of SNV-derived 9-mers is used as a representative peptide set for overall 9-mer expression. Filled violins with dotted
margins represent the distribution over all 9-mers in the respective set; solid lines represent the distribution over the subset of CPTAC-confirmed 9-mers.
See also Figures S4 and S5 and Table S1.et al., 2017). We combine the splicing phenotypes with variants
obtained from re-analysis of exome sequencing data for an
sQTL association study. A previous study considered alternative
splicing across 48 tissues from up to 620 donors (GTEx Con-
sortium et al., 2017; Saha et al., 2017). Another work considered
genetic determinants of alternative splicing in blood (Zhang
et al., 2015). Both studies were restricted to cis associations of
common germline variants with known isoform expression.
Large QTL association studies of common variants with gene
expression were reported on both TCGA (Gong et al., 2017; Li
et al., 2013) and non-TCGA datasets (GTEx Consortium et al.,
2017). In our study, we focus on variants that have been shown
to occur as somatic variants in some individuals but may also
occur in the germline genome in others. Those variants are typi-cally substantially less frequent (between 0.1% and 5% across
the cohort) than most common germline variants. The available
data provide sufficient statistical power to detect trans-sQTL
events that were difficult to detect previously (Fonseca et al.,
2017; GTEx Consortium et al., 2017; Lehmann et al., 2015).
Finally, our study comprehensively analyzes the extent to which
alternative splicing in tumors leads to cancer-specific RNA tran-
scripts that are translated into tumor-specific proteins and,
hence, may be targeted by immunotherapy. This has been
shown for specific genes for B cell lymphomas and ovarian can-
cers (Barrett et al., 2015; Vauchy et al., 2015). Here we use the
data from TCGA and GTEx to identify alternative splicing events
that are tumor specific and integrate them with re-analyzed
CPTAC MS data (Mertins et al., 2016; Zhang et al., 2016) toCancer Cell 34, 211–224, August 13, 2018 219
Table 1. Distribution of Intron-Spanning Polypeptide Sources
Type Median Mean
Germline variant 87,466.00 88,536.17
Somatic variant 172.00 610.94
Germline + somatic variant 42.00 208.63
Reference 518,831.00 518,831.00
Total 606,917.00 608,186.75show for two tumor types that the resulting mRNAs are indeed
translated into tumor-specific proteins that contain peptides
with the potential for MHC presentation.
We built a catalog of alternative splicing events found in these
samples with hundreds of thousands of events of whichz80%
are not annotated in GENCODE. In addition, we show that in
tumor samples we can observe on averagez20%more alterna-
tive splicing than in matched normal samples. The analysis of
RNA-seq data to extract splicing events is computationally
demanding and we hope that the identified and quantified alter-
native splicing events for all Pan-Cancer Atlas donors can be
used as a resource to simplify future analyses. One limitation
of this study, however, is that we only analyze bulk RNA-seq
and whole-exome sequencing data and we therefore have
limited power to detect and understand subclonal effects.
To understand the impact of somatic variants on alternative
splicing events, we performed a large-scale association study
of tumor variants with alternative splicing variation across the
genome. In order to characterize individual variants and to avoid
a burden-type strategy, we based our analysis on tumor variant
calls that overlap with recurrent highly confident somatic variant
calls allowing us to leverage changes at the germline as well as
the tumor levels. Associationmapping in trans is technically chal-
lenging and requires large cohorts such as the one considered
here. In particular, identifying and addressing confounders
appropriately is often challenging. Here we have accounted for
common confounders in the model and additionally checked
our results against correlation with purity, ploidy, patient sex,
as well as mutational load. Besides the aforementioned strong
effect of mutational load, we did find that the variant in PPP2R1A
is sex biased, which is expected as this gene is a known driver of
ovarian/uterine cancer. We also observed a correlation between
purity and one of the SF3B1 mutations. Eventually, this strategy
allowed us to identify a small number of known (SF3B1, U2AF1)
and a larger number of additional (TADA1, PPP2R1A, IDH1)
distal sQTLs that affect multiple alternative splicing events.
Overall, 385 genes have a splicing event that is the target of
one of these sQTLs. This illustrates the power of the pan-cancer
analyses of TCGA data to generate valuable hypotheses for
further mechanistic studies; for instance, to understand how a
somatic variant in IDH1 leads to widespread changes in alterna-
tive splicing across the genome. It is likely that splicing and
expression patterns are changed as an indirect, downstream ef-
fect of altered histone and demethylase patterns. The link of
TADA1 to alternative splicing events may be more direct, since
TADA1 interacts with SF3B5 and also shows a similar distribu-
tion of affected AS types as the known mutations in SF3B1.
PPP2R1A has previously been reported to affect nonsense-
mediated decay (NMD) (Sayani et al., 2008). We hypothesize220 Cancer Cell 34, 211–224, August 13, 2018that the loss-of-function somatic mutation in PPP2R1A leads
to a disruption of NMD function, which then leads to a detection
of AS variants that would otherwise get degraded by NMD. This
would explain why we find associations with alternative splicing.
In summary, this sQTL analysis, utilizing a large sample set size,
reveals promising additional long-range associations with
changes in exon composition of multiple genes.
Our study of the alternative splicing landscape demonstrated
that taking information on alternative splicing events into ac-
count is beneficial for characterizing cancer subtypes. A system-
atic analysis of splicing events in tumors enabled us to identify
genes that are recurrently alternatively spliced across multiple
cancer types. These events include well-understood examples
of alternative splicing changes promoting tumor development
(e.g.,BCL2L1, PKM) but also alternative splicing in cancer genes
for which the effect is not yet well understood (e.g., NUMB).
However, in this context we would like to note that even though
TCGA is a tremendous resource for cancer research, certain
biases are inherent to the dataset (mostly related to the design
of the study), which might not be representative in certain cir-
cumstances. For instance, TCGA tumors are treatment naive,
consist predominantly of primary tumors, and are biased toward
larger tumors with sufficient size to extract analysis material.
Within this study we cannot directly address this sampling bias
other than pointing it out and interpreting our results within its
context.
One important element of this study was to determine the
number of additional EEJs, which we called neojunctions, that
appear predominantly in tumors. We found that some samples
have a large degree of splicing aberration, where we can identify
thousands of neojunctions. Overall, we identifiedz251,000 neo-
junctions with an average ofz930 neojunctions per sample, and
many of them are recurrent: z18,000 of those neojunctions
appear in at least 100 samples. For comparison, there are only
13 somatic SNVs that were found in at least 100 tumors (the high-
ly recurrent SNVBRAFV600E being one of them). The vast number
of neojunctions and the high level of recurrence are very prom-
ising for future work.
To further develop the hypothesis of the importance of alterna-
tive splicing for the immune response to cancer, we have
analyzed to what extent neojunctions contribute to the transla-
tion of potential neoepitopes. This required the development of
an analysis pipeline to go from neojunctions to the predicted
translations of peptides around the neojunctions to the MS
confirmation, and theMHC-I binding prediction in order to deter-
mine which peptides are potential neoepitopes. Overall, by
considering splicing-derived in addition to SNV-derived pep-
tides, the fraction of samples with at least one CPTAC-confirmed
putative neoepitope increases from 30% to 75% for BRCA and
OV tumors. In addition, the splicing-derived putative neoepi-
topes have a high degree of recurrence, suggestive of potential
use in immunotherapeutic intervention.
In addition to the already completed analyses, we are currently
investigating further extensions and refinements. While the
current work only focuses on MHC-I alleles for peptide binding
predictions, incorporation of MHC-II alleles appears to be bene-
ficial as well (Sun et al., 2017). Also, MHC binding is essential but
not sufficient for a peptide to be capable of inducing an immune
response. Both the actual expression and processing of the
peptide as well as its immunogenicity need to be validated. The
tandem MS-based proteomics analysis employed in this
study aims at validating peptide expression. However, prote-
omics analysis alone cannot validate processing let alone
presentation of a given peptide by MHC. An important improve-
ment will be to replace this step; e.g., with MS-based immuno-
peptidomics (Bassani-Sternberg et al., 2016). Subsequently,
immunogenicity of the detected naturally processed neoepi-
topes could be determined via CD8+ T cell killing (Vitiello and
Zanetti, 2017). In addition, it may also be helpful to usemore sen-
sitive protein MS techniques; for instance, data-independent
acquisition MS (Gillet et al., 2012). Lastly, our current choice of
cancer types was mainly driven by availability within the TCGA
and CPTAC cohorts. We are actively working on extending this
work to other cancer types and into a more controlled experi-
mental setup.
In summary, in this study we considered the many differences
of alternative splicing in cancer compared with normal cells and
suggest that these differences are characteristic for individual
cancer types and could be used for the design of immunothera-
peutic interventions, such as chimeric antigen receptor T cell
therapy or personalized anti-cancer vaccines.STAR+METHODS
Detailed methods are provided in the online version of this paper
and include the following:
d KEY RESOURCES TABLE
d CONTACT FOR REAGENT AND RESOURCE SHARING
d METHOD DETAILSB Data Download
B RNA-Seq Alignment
B RNA-Seq Quality Control and Filtering
B Tumor Variant Calling
B Tumor Variant Filtering
B Gene Expression and Splicing Event Quantification
B Detection of Cancer-specific Introns
B Characterization of Neojunctions
B Identification of Rare Splicing Outliers
B t-SNE
B Differential Analysis of Splicing Events
B Filtering of Events and Variants for Somatic trans-As-
sociation
B Statistical Association of Genetic Variation and Alter-
native Splicing
B Derivation of Splicing-Derived Peptides
B MHC-I Binding Predictions
B Identification of Expressed Peptides
B Alternative Splicing-Derived Neoepitope Candidates
B SNV-Derived Neoepitope Candidates
B Estimation of RNA Expression of 9-mer Peptides
B Re-analysis on Representative Sample Subset
d DATA AND SOFTWARE AVAILABILITYSUPPLEMENTAL INFORMATION
Supplemental Information includes five figures and one table and can be found
with this article online at https://doi.org/10.1016/j.ccell.2018.07.001.ACKNOWLEDGMENTS
We would like to thank the ICGC/PCAWG Transcriptome Working Group (in
particular, Angela Brooks and Yuichi Shiraishi), Mitch Levesque, Mark Rubin,
Ruedi Aebersold, Alessandra Curioni, Michal Bassani-Sternberg, George Cou-
kos, and Nikolaus Schultz for fruitful discussions and feedback on project
design, specific methods, and the manuscript. We also gratefully acknowl-
edge the thorough review by the reviewers that has led to significant improve-
ments of the manuscript. Data used in this publication were generated by the
CPTAC (NCI/NIH). O.K. and T.S. acknowledge support from BMBF 031A535A.
This work was funded by MSKCC core funding, ETH Zurich core funding to
G.R., and SFA PHRT project grant PHRT #106 by the ETH Board to G.R.
AUTHOR CONTRIBUTIONS
G.R., A.K., and K.-V.L. conceived the work and designed experimental setup
and data analysis with input from N.C.T., O.K., C.S., and O.S. A.K. and K.-V.L.
jointly designed and implemented the RNA-seq analysis pipeline, with the help
of S.G.S. A.K. performed RNA-seq analyses, generation of splicing pheno-
types, and quantitative alternative splicing analysis. K.-V.L. performedQTL an-
alyses, statistical modeling, and differential analysis with input from O.S. M.H.
and A.K. contributed the splicing graph-derived peptides. Peptide filtering was
the result of discussions among G.R., N.C.T., A.K., M.H., and K.-V.L. N.C.T.
contributed the MHC binding predictions and, with the help of O.K. and T.S.,
performed the MS confirmation analyses. A.K., K.-V.L., G.R., C.S., and
N.C.T. jointly wrote the manuscript. All authors provided feedback on manu-
script drafts.
DECLARATION OF INTERESTS
Michael Seiler, Peter G. Smith, Ping Zhu, Silvia Buonamici, and Lihua Yu are
employees of H3 Biomedicine, Inc. Parts of this work are the subject of a pat-
ent application: WO2017040526 titled ‘‘Splice variants associated with neo-
morphic sf3b1 mutants.’’ Shouyoung Peng, Anant A. Agrawal, James Pala-
cino, and Teng Teng are employees of H3 Biomedicine, Inc. Andrew D.
Cherniack, Ashton C. Berger, and Galen F. Gao receive research support
from Bayer Pharmaceuticals. Gordon B. Mills serves on the External Scientific
Review Board of Astrazeneca. Anil Sood is on the Scientific Advisory Board for
Kiyatec and is a shareholder in BioPath. Jonathan S. Serody receives funding
from Merck, Inc. Kyle R. Covington is an employee of Castle Biosciences, Inc.
Preethi H. Gunaratne is founder, CSO, and shareholder of NextmiRNA Thera-
peutics. Christina Yau is a part-time employee/consultant at NantOmics. Franz
X. Schaub is an employee and shareholder of SEngine PrecisionMedicine, Inc.
Carla Grandori is an employee, founder, and shareholder of SEngine Precision
Medicine, Inc. Robert N. Eisenman is a member of the Scientific Advisory
Boards and shareholder of Shenogen Pharma and Kronos Bio. Daniel J. Wei-
senberger is a consultant for Zymo Research Corporation. Joshua M. Stuart is
the founder of Five3 Genomics and shareholder of NantOmics. Marc T.
Goodman receives research support from Merck, Inc. Andrew J. Gentles is
a consultant for Cibermed. Charles M. Perou is an equity stock holder, consul-
tant, and Board of Directors member of BioClassifier and GeneCentric Diag-
nostics and is also listed as an inventor on patent applications on the Breast
PAM50 and Lung Cancer Subtyping assays. Matthew Meyerson receives
research support from Bayer Pharmaceuticals; is an equity holder in, consul-
tant for, and Scientific Advisory Board chair for OrigiMed; and is an inventor of
a patent for EGFR mutation diagnosis in lung cancer, licensed to LabCorp.
Eduard Porta-Pardo is an inventor of a patent for domainXplorer. Han Liang
is a shareholder and scientific advisor of Precision Scientific and Eagle Nebula.
Da Yang is an inventor on a pending patent application describing the use of
antisense oligonucleotides against specific lncRNA sequence as diagnostic
and therapeutic tools. Yonghong Xiao was an employee and shareholder of
TESARO, Inc. Bin Feng is an employee and shareholder of TESARO, Inc.
Carter Van Waes received research funding for the study of IAP inhibitor
ASTX660 through a Cooperative Agreement between NIDCD, NIH, and Astex
Pharmaceuticals. Raunaq Malhotra is an employee and shareholder of Seven
Bridges, Inc. Peter W. Laird serves on the Scientific Advisory Board for
AnchorDx. Joel Tepper is a consultant at EMD Serono. Kenneth Wang serves
on the Advisory Board for Boston Scientific, Microtech, and Olympus. AndreaCancer Cell 34, 211–224, August 13, 2018 221
Califano is a founder, shareholder, and advisory board member of Darwin-
Health, Inc and a shareholder and advisory board member of Tempus. Toni
K. Choueiri serves as needed on advisory boards for Bristol-Myers Squibb,
Merck, and Roche. Lawrence Kwong receives research support from Array
BioPharma. Sharon E. Plon is a member of the Scientific Advisory Board for
Baylor Genetics Laboratory. Beth Y. Karlan serves on the Advisory Board of
Invitae.
Received: February 16, 2018
Revised: March 30, 2018
Accepted: July 2, 2018
Published: August 2, 2018
REFERENCES
Agrawal, S., and Eng, C. (2006). Differential expression of novel naturally
occurring splice variants of PTEN and their functional consequences in
Cowden syndrome and sporadic breast cancer. Hum. Mol. Genet. 15,
777–787.
Alsafadi, S., Houy, A., Battistella, A., Popova, T., Wassef, M., Henry, E., Tirode,
F., Constantinou, A., Piperno-Neumann, S., Roman-Roman, S., et al. (2016).
Cancer-associated SF3B1 mutations affect alternative splicing by promoting
alternative branchpoint usage. Nat. Commun. 7, 10615.
Andreatta, M., and Nielsen, M. (2016). Gapped sequence alignment using arti-
ficial neural networks: application to the MHC class I system. Bioinformatics
32, 511–517.
Barrett, C.L., DeBoever, C., Jepsen, K., Saenz, C.C., Carson, D.A., and Frazer,
K.A. (2015). Systematic transcriptome analysis reveals tumor-specific iso-
forms for ovarian cancer diagnosis and therapy. Proc. Natl. Acad. Sci. USA
112, E3050–E3057.
Bassani-Sternberg, M., Br€aunlein, E., Klar, R., Engleitner, T., Sinitcyn, P.,
Audehm, S., Straub, M., Weber, J., Slotta-Huspenina, J., Specht, K., et al.
(2016). Direct identification of clinically relevant neoepitopes presented on
native human melanoma tissue by mass spectrometry. Nat. Commun.
7, 13404.
Bjørklund, S.S., Panda, A., Kumar, S., Seiler, M., Robinson, D., Gheeya, J.,
Yao, M., Alnæs, G.I.G., Toppmeyer, D., Riis, M., et al. (2017). Widespread
alternative exon usage in clinically distinct subtypes of invasive ductal carci-
noma. Sci. Rep. 7, 5568.
Blum, A., Wang, P., and Zenklusen, J.C. (2018). SnapShot: TCGA-analyzed tu-
mors. Cell 173, 530.
Brooks, A.N., Choi, P.S., de Waal, L., Sharifnia, T., Imielinski, M., Saksena, G.,
Pedamallu, C.S., Sivachenko, A., Rosenberg, M., Chmielecki, J., et al. (2014).
A pan-cancer analysis of transcriptome changes associated with somatic mu-
tations in U2AF1 reveals commonly altered splicing events. PLoS One 9,
e87361.
Cancer Genome Atlas Network (2012). Comprehensive molecular character-
ization of human colon and rectal cancer. Nature 487, 330–337.
Cancer Genome Atlas Research Network (2008). Comprehensive genomic
characterization defines human glioblastoma genes and core pathways.
Nature 455, 1061–1068.
Cartegni, L., Chew, S.L., and Krainer, A.R. (2002). Listening to silence and un-
derstanding nonsense: exonic mutations that affect splicing. Nat. Rev. Genet.
3, 285–298.
Celebi, J.T., Wanner, M., Ping, X.L., Zhang, H., and Peacocke, M. (2000).
Association of splicing defects in PTEN leading to exon skipping or partial
intron retention in Cowden syndrome. Hum. Genet. 107, 234–238.
Chen, H.J., Romigh, T., Sesock, K., and Eng, C. (2017). Characterization of
cryptic splicing in germline PTEN intronic variants in Cowden syndrome.
Hum. Mutat. 38, 1372–1377.
Chung, C.H., Bernard, P.S., and Perou, C.M. (2002). Molecular portraits and
the family tree of cancer. Nat. Genet. 32 Suppl, 533–540.
Climente-Gonza´lez, H., Porta-Pardo, E., Godzik, A., and Eyras, E. (2017). The
functional impact of alternative splicing in cancer. Cell Rep. 20, 2215–2226.222 Cancer Cell 34, 211–224, August 13, 2018Clower, C.V., Chatterjee, D., Wang, Z., Cantley, L.C., Vander Heiden, M.G.,
and Krainer, A.R. (2010). The alternative splicing repressors hnRNP A1/A2
and PTB influence pyruvate kinase isoform expression and cell metabolism.
Proc. Natl. Acad. Sci. USA 107, 1894–1899.
David, C.J., Chen,M., Assanah,M., Canoll, P., andManley, J.L. (2010). HnRNP
proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in
cancer. Nature 463, 364–368.
Djebali, S., Davis, C.A., Merkel, A., Dobin, A., Lassmann, T., Mortazavi, A.,
Tanzer, A., Lagarde, J., Lin, W., Schlesinger, F., et al. (2012). Landscape of
transcription in human cells. Nature 489, 101–108.
Dobin, A., Davis, C.A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut,
P., Chaisson,M., andGingeras, T.R. (2013). STAR: ultrafast universal RNA-seq
aligner. Bioinformatics 29, 15–21.
Edwards, N.J., Oberti, M., Thangudu, R.R., Cai, S., McGarvey, P.B., Jacob, S.,
Madhavan, S., and Ketchum, K.A. (2015). The CPTAC data portal: a resource
for cancer proteomics research. J. Proteome Res. 14, 2707–2713.
Ellrott, K., Bailey, M.H., Saksena, G., Covington, K.R., Kandoth, C., Stewart,
C., Hess, J., Ma, S., Chiotti, K.E., McLellan, M., et al. (2018). Scalable open sci-
ence approach for mutation calling of tumor exomes using multiple genomic
pipelines. Cell Syst. 6, 271–281.e7.
Fonseca, N.A., Kahles, A., Lehmann, K.-V., Calabrese, C., Chateigner, A.,
Davidson, N.R., Demircioglu, D., He, Y., Lamaze, F.C., Li, S., et al. (2017).
Pan-cancer study of heterogeneous RNA aberrations. bioRxiv. https://doi.
org/10.1101/183889.
Frampton, G.M., Ali, S.M., Rosenzweig, M., Chmielecki, J., Lu, X., Bauer, T.M.,
Akimov, M., Bufill, J.A., Lee, C., Jentz, D., et al. (2015). Activation of MET via
diverse exon 14 splicing alterations occurs in multiple tumor types and confers
clinical sensitivity to MET inhibitors. Cancer Discov. 5, 850–859.
Furney, S.J., Pedersen,M., Gentien, D., Dumont, A.G., Rapinat, A., Desjardins,
L., Turajlic, S., Piperno-Neumann, S., de la Grange, P., Roman-Roman, S.,
et al. (2013). SF3B1 mutations are associated with alternative splicing in uveal
melanoma. Cancer Discov. 3, 1122–1129.
Futreal, P.A., Andrew Futreal, P., Kasprzyk, A., Birney, E., Mullikin, J.C.,
Wooster, R., and Stratton, M.R. (2001). Cancer and genomics. Nature 409,
850–852.
Gillet, L.C., Navarro, P., Tate, S., Ro¨st, H., Selevsek, N., Reiter, L., Bonner, R.,
and Aebersold, R. (2012). Targeted data extraction of the MS/MS spectra
generated by data-independent acquisition: a new concept for consistent
and accurate proteome analysis. Mol. Cell. Proteomics 11, O111.016717.
Gong, J., Mei, S., Liu, C., Xiang, Y., Ye, Y., Zhang, Z., Feng, J., Liu, R., Diao, L.,
Guo, A.-Y., et al. (2017). PancanQTL: systematic identification of cis-eQTLs
and trans-eQTLs in 33 cancer types. Nucleic Acids Res. 46, D971–D976.
Graubert, T.A., Shen, D., Ding, L., Okeyo-Owuor, T., Lunn, C.L., Shao, J.,
Krysiak, K., Harris, C.C., Koboldt, D.C., Larson, D.E., et al. (2012). Recurrent
mutations in the U2AF1 splicing factor in myelodysplastic syndromes. Nat.
Genet. 44, 53–57.
Greenman, C., Stephens, P., Smith, R., Dalgliesh, G.L., Hunter, C., Bignell, G.,
Davies, H., Teague, J., Butler, A., Stevens, C., et al. (2007). Patterns of somatic
mutation in human cancer genomes. Nature 446, 153–158.
GTEx Consortium, Laboratory, Data Analysis & Coordinating Center
(LDACC)—Analysis Working Group, Statistical Methods groups—Analysis
Working Group, Enhancing GTEx (eGTEx) groups, NIH Common Fund, NIH/
NCI, NIH/NHGRI, NIH/NIMH, NIH/NIDA, Biospecimen Collection Source
Site—NDRI, et al. (2017). Genetic effects on gene expression across human
tissues. Nature 550, 204–213.
Hatje, K., Rahman, R.-U., Vidal, R.O., Simm, D., Hammesfahr, B., Bansal, V.,
Rajput, A., Mickael, M.E., Sun, T., Bonn, S., et al. (2017). The landscape of hu-
man mutually exclusive splicing. Mol. Syst. Biol. 13, 959.
Hoadley, K.A., Yau, C., Wolf, D.M., Cherniack, A.D., Tamborero, D., Ng, S.,
Leiserson, M.D.M., Niu, B., McLellan, M.D., Uzunangelov, V., et al. (2014).
Multiplatform analysis of 12 cancer types reveals molecular classification
within and across tissues of origin. Cell 158, 929–944.
Kahles, A., Ong, C.S., and R€atsch, G. (2016). SplAdder: identification, quanti-
fication and testing of alternative splicing events from RNA-seq data.
Bioinformatics 32, 1840–1847.
Kohlbacher, O., Reinert, K., Gro¨pl, C., Lange, E., Pfeifer, N., Schulz-Trieglaff,
O., and Sturm, M. (2007). TOPP–the OpenMS proteomics pipeline.
Bioinformatics 23, e191–e197.
Kovacevic, Z., Sivagurunathan, S., Mangs, H., Chikhani, S., Zhang, D., and
Richardson, D.R. (2011). The metastasis suppressor, N-myc downstream
regulated gene 1 (NDRG1), upregulates p21 via p53-independent mecha-
nisms. Carcinogenesis 32, 732–740.
Lefave, C.V., Squatrito, M., Vorlova, S., Rocco, G.L., Brennan, C.W., Holland,
E.C., Pan, Y.-X., and Cartegni, L. (2011). Splicing factor hnRNPH drives an
oncogenic splicing switch in gliomas. EMBO J. 30, 4084–4097.
Lehmann, K.-V., Kahles, A., Kandoth, C., Lee, W., Schultz, N., Stegle, O., and
R€atsch, G. (2015). Integrative genome-wide analysis of the determinants of
RNA splicing in kidney renal clear cell carcinoma. Pac. Symp. Biocomput.
20, 44–55.
Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G.,
Abecasis, G., Durbin, R., and 1000 Genome Project Data Processing
Subgroup. (2009). The sequence alignment/map format and SAMtools.
Bioinformatics 25, 2078–2079.
Li, Q., Seo, J.-H., Stranger, B., McKenna, A., Pe’er, I., Laframboise, T., Brown,
M., Tyekucheva, S., and Freedman, M.L. (2013). Integrative eQTL-based ana-
lyses reveal the biology of breast cancer risk loci. Cell 152, 633–641.
Li, Y., Sun, N., Lu, Z., Sun, S., Huang, J., Chen, Z., and He, J. (2017).
Prognostic alternative mRNA splicing signature in non-small cell lung cancer.
Cancer Lett. 393, 40–51.
Lippert, C., Casale, F., Rakitsch, B., and Stegle, O. (2014). LIMIX: genetic anal-
ysis of multiple traits. bioRxiv. https://doi.org/10.1101/003905.
Marcelino Meliso, F., Hubert, C.G., Favoretto Galante, P.A., and Penalva, L.O.
(2017). RNA processing as an alternative route to attack glioblastoma. Hum.
Genet. 136, 1129–1141.
McKenna, A., Hanna, M., Banks, E., Sivachenko, A., Cibulskis, K., Kernytsky,
A., Garimella, K., Altshuler, D., Gabriel, S., Daly, M., et al. (2010). The genome
analysis toolkit: a MapReduce framework for analyzing next-generation DNA
sequencing data. Genome Res. 20, 1297–1303.
Mertins, P., Mani, D.R., Ruggles, K.V., Gillette, M.A., Clauser, K.R., Wang, P.,
Wang, X., Qiao, J.W., Cao, S., Petralia, F., et al. (2016). Proteogenomics
connects somatic mutations to signalling in breast cancer. Nature 534, 55.
Nellore, A., Jaffe, A.E., Fortin, J.-P., Alquicira-Herna´ndez, J., Collado-Torres,
L., Wang, S., Phillips, R.A., III, Karbhari, N., Hansen, K.D., Langmead, B.,
et al. (2016). Human splicing diversity and the extent of unannotated splice
junctions across human RNA-seq samples on the sequence read archive.
Genome Biol. 17, 266.
Okumura, N., Yoshida, H., Kitagishi, Y., Nishimura, Y., andMatsuda, S. (2011).
Alternative splicings on p53, BRCA1 and PTEN genes involved in breast can-
cer. Biochem. Biophys. Res. Commun. 413, 395–399.
Paik, P.K., Drilon, A., Fan, P.-D., Yu, H., Rekhtman, N., Ginsberg, M.S., Borsu,
L., Schultz, N., Berger, M.F., Rudin, C.M., et al. (2015). Response toMET inhib-
itors in patients with stage IV lung adenocarcinomas harboring METmutations
causing exon 14 skipping. Cancer Discov. 5, 842–849.
Pece, S., Confalonieri, S., Romano, P.R., and Di Fiore, P.P. (2011). NUMB-ing
down cancer by more than just a NOTCH. Biochim. Biophys. Acta
1815, 26–43.
Pedregosa, F., Varoquaux, G., Gramfort, A., Michel, V., Thirion, B., Grisel, O.,
Blondel, M., Prettenhofer, P., Weiss, R., Dubourg, V., et al. (2011). Scikit-learn:
machine learning in Python. J. Mach. Learn. Res. 12, 2825–2830.
Pickrell, J.K., Pai, A.A., Gilad, Y., and Pritchard, J.K. (2010). Noisy
splicing drives mRNA isoform diversity in human cells. PLoS Genet. 6,
e1001236.
Robertson, A.G., Shih, J., Yau, C., Gibb, E.A., Oba, J., Mungall, K.L., Hess,
J.M., Uzunangelov, V., Walter, V., Danilova, L., et al. (2017). Integrative analysis
identifies four molecular and clinical subsets in uveal melanoma. Cancer Cell
33, 151.Rossi, D., Bruscaggin, A., Spina, V., Rasi, S., Khiabanian, H., Messina, M.,
Fangazio, M., Vaisitti, T., Monti, S., Chiaretti, S., et al. (2011). Mutations of
the SF3B1 splicing factor in chronic lymphocytic leukemia: association with
progression and fludarabine-refractoriness. Blood 118, 6904–6908.
Ro¨st, H.L., Sachsenberg, T., Aiche, S., Bielow, C., Weisser, H., Aicheler, F.,
Andreotti, S., Ehrlich, H.-C., Gutenbrunner, P., Kenar, E., et al. (2016).
OpenMS: a flexible open-source software platform for mass spectrometry
data analysis. Nat. Methods 13, 741–748.
Roy, B., Haupt, L.M., andGriffiths, L.R. (2013). Review: alternative splicing (AS)
of genes as an approach for generating protein complexity. Curr. Genomics
14, 182–194.
Saha, A., Kim, Y., Gewirtz, A.D.H., Jo, B., Gao, C., McDowell, I.C., GTEx
Consortium, Engelhardt, B.E., and Battle, A. (2017). Co-expression networks
reveal the tissue-specific regulation of transcription and splicing. Genome
Res. 27, 1843–1858.
Sayani, S., Janis, M., Lee, C.Y., Toesca, I., and Chanfreau, G.F. (2008).
Widespread impact of nonsense-mediated mRNA decay on the yeast intro-
nome. Mol. Cell 31, 360.
Schafer, S., Miao, K., Benson, C.C., Heinig, M., Cook, S.A., and Hubner, N.
(2015). Alternative splicing signatures in RNA-seq data: percent spliced in
(PSI). Curr. Protoc. Hum. Genet. 87, 11–16.
Sebestye´n, E., Zawisza, M., and Eyras, E. (2015). Detection of recurrent alter-
native splicing switches in tumor samples reveals novel signatures of cancer.
Nucleic Acids Res. 43, 1345–1356.
Shukla, S.A., Rooney, M.S., Rajasagi, M., Tiao, G., Dixon, P.M., Lawrence,
M.S., Stevens, J., Lane, W.J., Dellagatta, J.L., Steelman, S., et al. (2015).
Comprehensive analysis of cancer-associated somatic mutations in class I
HLA genes. Nat. Biotechnol. 33, 1152–1158.
Srebrow, A., and Kornblihtt, A.R. (2006). The connection between splicing and
cancer. J. Cell Sci. 119, 2635–2641.
Stephens, P.J., Greenman, C.D., Fu, B., Yang, F., Bignell, G.R., Mudie, L.J.,
Pleasance, E.D., Lau, K.W., Beare, D., Stebbings, L.A., et al. (2011). Massive
genomic rearrangement acquired in a single catastrophic event during cancer
development. Cell 144, 27–40.
Sun, Z., Chen, F., Meng, F., Wei, J., and Liu, B. (2017). MHC class II restricted
neoantigen: a promising target in tumor immunotherapy. Cancer Lett.
392, 17–25.
Van der Auwera, G.A., Carneiro, M.O., Hartl, C., Poplin, R., del Angel, G.,
Levy-Moonshine, A., Jordan, T., Shakir, K., Roazen, D., Thibault, J., et al.
(2013). From fastQ data to high-confidence variant calls: the genome anal-
ysis toolkit best practices pipeline. Curr. Protoc. Bioinformatics 43,
11.10.1–11.10.33.
Van der Maaten, L., and Hinton, G. (2008). Visualizing data using t-SNE.
J. Mach. Learn. Res. 9, 2579–2605.
Vauchy, C., Gamonet, C., Ferrand, C., Daguindau, E., Galaine, J., Beziaud, L.,
Chauchet, A., Henry Dunand, C.J., Deschamps, M., Rohrlich, P.S., et al.
(2015). CD20 alternative splicing isoform generates immunogenic CD4 helper
T epitopes. Int. J. Cancer 137, 116–126.
Venables, J.P., Klinck, R., Koh, C., Gervais-Bird, J., Bramard, A., Inkel, L.,
Durand, M., Couture, S., Froehlich, U., Lapointe, E., et al. (2009). Cancer-
associated regulation of alternative splicing. Nat. Struct. Mol. Biol. 16,
670–676.
Vitiello, A., and Zanetti, M. (2017). Neoantigen prediction and the need for vali-
dation. Nat. Biotechnol. 35, 815–817.
Wang, E.T., Sandberg, R., Luo, S., Khrebtukova, I., Zhang, L., Mayr, C.,
Kingsmore, S.F., Schroth, G.P., and Burge, C.B. (2008). Alternative isoform
regulation in human tissue transcriptomes. Nature 456, 470–476.
Wang, Y., Chen, D., Qian, H., Tsai, Y.S., Shao, S., Liu, Q., Dominguez, D., and
Wang, Z. (2014). The splicing factor RBM4 controls apoptosis, proliferation,
and migration to suppress tumor progression. Cancer Cell 26, 374–389.
Wang, X., Codreanu, S.G., Wen, B., Li, K., Chambers, M., Liebler, D.C., and
Zhang, B. (2017). Detection of proteome diversity resulted from alternative
splicing is limited by trypsin cleavage specificity. Mol. Cell. Proteomics 17,
422–430.Cancer Cell 34, 211–224, August 13, 2018 223
Wilks, C., Maltbie, D., Diekhans, M., and Haussler, D. (2013). CGHub: kick-
starting the worldwide genome web. Proceedings of the Asia-Pacific
Advanced Network 35, https://doi.org/10.7125/APAN.35.1.
Yan, H., Williams Parsons, D., Jin, G., McLendon, R., Ahmed Rasheed, B.,
Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G.J., et al. (2009).
IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med. 360, 765–773.
Yen, K.E., Bittinger, M.A., Su, S.M., and Fantin, V.R. (2010). Cancer-associ-
ated IDH mutations: biomarker and therapeutic opportunities. Oncogene 29,
6409–6417.
Zhang, X., Joehanes, R., Chen, B.H., Huan, T., Ying, S., Munson, P.J.,
Johnson, A.D., Levy, D., and O’Donnell, C.J. (2015). Identification of common224 Cancer Cell 34, 211–224, August 13, 2018genetic variants controlling transcript isoform variation in human whole blood.
Nat. Genet. 47, 345–352.
Zhang, H., Liu, T., Zhang, Z., Payne, S.H., Zhang, B., McDermott, J.E., Zhou,
J.-Y., Petyuk, V.A., Chen, L., Ray, D., et al. (2016). Integrated proteogenomic
characterization of human high-grade serous ovarian cancer. Cell 166,
755–765.
Zhu, J., Chen, Z., and Yong, L. (2017). Systematic profiling of alternative
splicing signature reveals prognostic predictor for ovarian cancer. Gynecol.
Oncol. 148, 368–374.
STAR+METHODSKEY RESOURCES TABLEREAGENT or RESOURCE SOURCE IDENTIFIER
Deposited Data
TCGA Unified MC3 Variant Calls Ellrott et al., 2018 https://www.synapse.org/#!Synapse:
syn7214402
Comprehensive set of alternative splicing events This Paper https://gdc.cancer.gov/about-data/
publications/PanCanAtlas-Splicing-2018
HLA types Shukla et al., 2015 https://www.synapse.org/#!Synapse:
syn5974638
Neoepitopes This paper https://www.synapse.org/#!Synapse:
syn12180140
Tumor variants used for association This paper https://www.synapse.org/#!Synapse:
syn12179113
Variants significantly associated with splicing This paper https://gdc.cancer.gov/about-data/
publications/PanCanAtlas-Splicing-2018
RNA-Seq samples from GTEx cohort
(full list of used IDs available at https://gdc.cancer.
gov/about-data/publications/PanCanAtlas-
Splicing-2018)
GTEx Consortium et al., 2017 https://www.gtexportal.org/home/
RNA-Seq samples from TCGA cohort
(full list of used IDs available at https://gdc.cancer.
gov/about-data/publications/PanCanAtlas-
Splicing-2018)
Blum et al., 2018 https://gdc.cancer.gov/
Protein MS samples from CPTAC cohort
(full list of used IDs available at https://gdc.cancer.
gov/about-data/publications/PanCanAtlas-
Splicing-2018)
Zhang et al., 2016
Mertins et al., 2016
https://cptac-data-portal.georgetown.
edu/cptacPublic/
Software and Algorithms
SplAdder Kahles et al., 2016 https://github.com/ratschlab/spladder
LIMIX Lippert et al., 2014 https://github.com/limix/limix
GATK McKenna et al., 2010 https://software.broadinstitute.org/gatk/
STAR Dobin et al., 2013 https://github.com/alexdobin/STAR
Samtools/HTSlib Li et al., 2009 http://www.htslib.org/
Custom analysis scripts This Paper https://github.com/ratschlab/pancanatlas_
code_publicCONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Gunnar
R€atsch (gunnar.ratsch@ratschlab.org).
METHOD DETAILS
Data Download
RawRNA-sequencing samples in FASTQ format andwhole-exome sequencing alignment files in BAM format were downloaded from
the CancerGenomicsHub (CGHub) at UCSC (Wilks et al., 2013) using the cgtools software. CGHub has been decommissioned over
the course of this project’s duration. All data is now available at the Genomic Data Commons (https://gdc.cancer.gov/, more
information below). Proteomics data for TCGA breast and ovarian cancer samples were downloaded from the CPTAC data portal
(Edwards et al., 2015).Cancer Cell 34, 211–224.e1–e6, August 13, 2018 e1
RNA-Seq Alignment
All previously downloaded RNA-seq samples were individually aligned using a uniform processing pipeline based on the STAR
aligner (Dobin et al., 2013). Due to the long duration of the whole project and the extensive analyses, we used two different alignment
strategies to include further samples in a second run. While almost all analyses were performed with both strategies, the sQTL anal-
ysis was completed on strategy 1 only and the neoepitope analysis was completed on the junctions resulting from the intersection of
strategies 1 and 2., For the remaining analysis, we compared all results and found no significant differences between the two align-
ment strategies.
Strategy 1
The STAR software (version 2.4.0i) was used in a 2-pass setup, where the first alignment pass was used to identify non-annotated
junctions in the input data, allowing for the construction of a genome index containing non-annotetd junctions. The second pass
alignment was then performed against the junction-aware index, allowing for amore sensitive recovery of non-annotated splice junc-
tion from the data. A complete set of command line parameters:
1st Pass. STAR –genomeDir GENOME –readFilesIn READ1 READ2 –runThreadN 4 –outFilterMultimapScoreRange 1 –outFilter
MultimapNmax 20 –outFilterMismatchNmax 10 –alignIntronMax 500000 –alignMatesGapMax 1000000 –sjdbScore 2 –align
SJDBoverhangMin 1 –genomeLoad NoSharedMemory –readFilesCommand cat –outFilterMatchNminOverLread 0.33 –outFilter
ScoreMinOverLread 0.33 –sjdbOverhang 100 –outSAMstrandField intronMotif –outSAMtype None –outSAMmode None.
Re-indexing. STAR –runMode genomeGenerate –genomeDir GENOME_TMP –genomeFastaFiles GENOME_FASTA –sjdb
Overhang 100 –runThreadN 4 –sjdbFileChrStartEnd SJ.out.tab (from 1st pass)
2nd Pass. STAR –genomeDir GENOME_TMP –readFilesIn READ1 READ2 –runThreadN 4 –outFilterMultimapScoreRange 1 –out
FilterMultimapNmax 20 –outFilterMismatchNmax 10 –alignIntronMax 500000 –alignMatesGapMax 1000000 –sjdbScore 2 –align
SJDBoverhangMin 1 –genomeLoad NoSharedMemory –limitBAMsortRAM 70000000000 –readFilesCommand cat –outFilterMatch
NminOverLread 0.33 –outFilterScoreMinOverLread 0.33 –sjdbOverhang 100 –outSAMstrandField intronMotif –outSAMattributes NH
HI NM MD AS XS –outSAMunmapped Within –outSAMtype BAM SortedByCoordinate –outSAMheaderHD @HD VN:1.4 –out
SAMattrRGline ID SM:
Strategy 2
Again, this strategy comprises a two-pass alignment approach. As a difference to strategy 1, a newer version of the STAR aligner was
used (2.5.3a), that re-creates the index augmented with non-annotated junctions on the fly and does not require manual rebuild of the
reference genome index. Hence only a single run per sample was necessary. The full list of command line parameters was as follows:
STAR –genomeDir GENOME –readFilesIn READ1 READ2 –runThreadN 4 –outFilterMultimapScoreRange 1 –outFilterMultimap
Nmax 20 –outFilterMismatchNmax 10 –alignIntronMax 500000 –alignMatesGapMax 1000000 –sjdbScore 2 –alignSJDBoverhang
Min 1 –genomeLoad NoSharedMemory –limitBAMsortRAM 70000000000 –readFilesCommand cat –outFilterMatchNminOverLread
0.33 –outFilterScoreMinOverLread 0.33 –sjdbOverhang 100 –outSAMstrandField intronMotif –outSAMattributes NH HI NM MD AS
XS –sjdbGTFfile GENCODE_ANNOTATION –limitSjdbInsertNsj 2000000 –outSAMunmapped None –outSAMtype BAM Sorted
ByCoordinate –outSAMheaderHD @HD VN:1.4 –outSAMattrRGline ID::<ID> –twopassMode Basic –outSAMmultNmax 1
RNA-Seq Quality Control and Filtering
For each RNA-seq library we ran the FastQC analysis tool (version 0.11.6) and collected library statistics. Further we collected
alignment statistics and computed a bias score between 3 and 50 end of each gene tomeasure possible degradation. Based on these
measurements, we developed a scoring scheme to exclude samples. A sample could be flagged as low-quality if at least 3 of key
FastQC criteria were labeled as fail (criteria: per base quality, per sequence quality, gc content, N content, sequence overrepresen-
tation), the degradation score was larger than Q3 + 1.5xIQR, the GC content was more than 1.5xIQR below Q1 or above Q3 or the
number of reads wasmore than 1.5xIQR belowQ1 or above Q3. A sample was excluded, if it was flagged for at least three low quality
criteria, the degradation score was larger than Q3 + 3xIQR, the GC content was more than 3xIQR below Q1 or above Q3 or the
number of reads was more than 3xIQR below Q1 or above Q3.
Tumor Variant Calling
We have used Picard (version 1.87) and theGenome Analysis Toolkit (GATK, version 3.4.46) (McKenna et al., 2010) for variant calling.
We followed the good-practice guidelines for variant calling withGATK (Van der Auwera et al., 2013).We omitted a duplicate-marking
of the input files as the alignment versions downloaded from CGHub already had duplicates marked. Each alignment file was then
stripped of all unmapped reads and re-indexed using samtools (version 1.2).
Utilizing the capture-region information for the exome capture procedure of each file and dbSNP (version 138), the 1000 Genome
Project Phase 1 and the Mills and 1000G gold standard set as compendium of known sites, we usedGATK for base quality score re-
calibration.
Re-calibration Step 1
java -jar GenomeAnalysisTK.jar -T BaseRecalibrator -R <genome.fasta> -I <alignment.bam> -knownSites <known_sites> -L
<capture_region> -o <outfile1> -nct <threads>
Re-calibration Step 2
java -jar GenomeAnalysisTK.jar -T PrintReads -R <genome.fasta> -I <alignment.bam> -BQSR <outfile1> -o <outfile2> -nct
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Variant calling was then performed using theGATK Haplotype Caller. The calling limit was defined as a +/ 1kb window around all
genes in the GENCODE annotation (v19), including all intron regions.
Variant Calling
java -Xmx4g -Xms512m -Djava.io.tmpdir=<TMPDIR> -jar GenomeAnalysisTK.jar -T HaplotypeCaller -R <genome.fasta> -I
<alignment.bam> –dbsnp <dbsnp_v138.vcf> -o <outfile> –output_mode EMIT_ALL_CONFIDENT_SITES -ERC GVCF –variant_
index_type LINEAR –variant_index_parameter 128000 -pairHMM VECTOR_LOGLESS_CACHING -mbq 15 –minPruning
5 -S STRICT –activeRegionOut <outfile_region> –activityProfileOut <outfile_profile> -L <calling_limit.bed> -nct <threads>
The gVCF files created in the previous step for each sample were then merged in an iterative process until less than 100 merged
files remained:
java -jar GenomeAnalysisTK.jar -T CombineGVCFs -R <genome.fasta> –variant <s1>. –variant <sN> -o <outfile_merged1>
The merged gVCF files were then used for joint variant calling on each chromosome independently using the GATK:
java -Xmx16g -jar GenomeAnalysisTK.jar -T GenotypeGVCFs -L <chr> -nt <threads> –dbsnp <dbsnp_v138.vcf> -R
<genome.fasta> –variant <outfile_merged1>. –variant <outfile_mergedN> -o <outfile_final>
Tumor Variant Filtering
Tumor variant calls have been filtered in the following way: Variants that have less than 100 samples with valid calls, quality of less
than 100, are multi-allelic or indels have been removed from analysis. We further required more than 5 alternate alleles for each poly-
morphic position. All variants have been encoded into an additive scheme with 0 representing the homozygous reference state, 1 the
heterozygous state and 2 the homozygous alternate allele. In this study, we ignore the existence of variants that appear sub-clonally.
For somatic variant calls the unfiltered MC3 calls from PanCanAtlas have been used (version 0.2.8; Synapse ID: syn7834470). From
that variant call set we extracted single nucleotide variants (SNVs) but excluded variants tagged by the following criteria:
d StrandBias
d contest
d oxog
d ndp
d pcadontuse
d nonpreferredpair
d badseq
d gapfiller
d common_in_exac
d PoN
We also required that at least three variant callers agree on a variant call and excluded variants which have a higher than 5%minor
allele frequency in the 1,000 genomes cohort. Non-recurrent variant calls (variants which appear in only one sample) have also been
excluded from further analysis. This filtering ensures a high-quality variant call set which includes intronic variants at exon
boundaries.
The somatic and tumor variant calls have subsequently been intersected, resulting in a total of 4,041 variant calls considered in this
analysis.
Gene Expression and Splicing Event Quantification
For expression counting we used a custom python script that counted a read towards a gene if at least one base of the read over-
lapped an exonic position of the gene. We did not count secondary alignments (as indicated in the BAM files with flag 256) and
masked regions from the annotation where multiple genes overlapped. We also generated a second set of expression counts
(non-alt) that excluded all genomic positions from counting that were annotated with both intron and exon.
Alternative splicing events were detected and quantified using theSplAdder toolkit (Kahles et al., 2016). Briefly, with the pipeline we
generated a sample-specific splicing graph per sample and gene, integrating additional information based on RNA-seq alignment
data. For each gene all graphs of all samples were then merged into a joint splicing graph. If a graph of a gene had more than
10,000 edges, we excluded it from further merging. Lastly, we pruned edges from the merged graphs if they were supported by
less than 10 samples in the cohort. This procedure resulted in a single merged graph per gene for all samples.
Subsequently, we quantified nodes and edges of themerged graph for all samples based on the RNA-seq alignments. Edges were
quantified as number of supporting spliced alignments and exons as mean read coverage over all exonic positions. From the
quantified graphs we detected all alternative events of the following types: exon skipping, intron retention, alternative 30 splice
site and alternative 50 splice site (Figure S1A). For each event we then computed percent spliced in (PSI) values based on the pre-
viously quantified splicing graphs.
Detection of Cancer-specific Introns
To account for cohort size and read length effects, this analysis was performed on a randomly selected subset of 40 tumor samples
from each tumor type (for all types with sufficient number of samples) and the RNA-seq reads were trimmed to a uniform length ofCancer Cell 34, 211–224.e1–e6, August 13, 2018 e3
50 nt if their length was exceeding this threshold. The detection and quantification of alternative splicing events was otherwise per-
formed as described above.
Characterization of Neojunctions
Starting with the splicing graphs for all genes that we generated previously, we removed all intron edges that could be confirmed with
at least 2 reads in at least 1%of samples (30) from theGTEx cohort. Before thresholding, junction counts were normalized for library
size differences. Further, samples with a library size (measured as the upper quartile expression of autosomal genes) of less than
2,500 were excluded from this analysis to exclude artifacts caused by low complexity libraries not caught by the global QC. We
then computed splicing complexity (the number of neojunctions) as the sum of the total number of splice graph edges confirmed
with at least 3 reads in a sample and at least 20 reads over the whole cohort as total sum over all genes of a sample.
For a ranking of neojunctions, we sorted all EEJswith an increased specificity towards tumor samples requiring aminimumnumber
of spliced alignments across the EEJ per sample to count it as expressed (tumor: 10 spliced reads, normals: 3 spliced reads, GTEx:
2 spliced reads). Further, we removed all junctions that were present in more than 1% of GTEx or TCGA normal samples or had a
higher mean expression in TCGA normals compared to TCGA tumor samples (within the same cancer type). We then ranked all
EEJs by predominant occurrence in tumor samples based on Fisher’s exact test. To aggregate over multiple events in a gene, we
show only the event with the strongest effect.
Identification of Rare Splicing Outliers
For outlier detection we applied a set of hard filter criteria on our full set of detected alternative splicing events. To allow for a stable
and comparable analysis, we only checked for outliers in cancer types with at least 100 samples available. For each event we
required that the maximum spread of PSI values in the GTEx cohort as well as within the TCGA normal sample is at most 0.3. We
further excluded an event if it i) had less than 80 samples with sufficiently many reads (N = 10) to compute a PSI, ii) had a spread
of PSI values in the respective cancer type of less than 0.4. We then computed the number of samples with a PSI value of at least
10 times the inter-quartile range above/below the upper/lower quartile and marked them as outliers. If we found less than 5 or more
than 100 outliers for the event and cancer-type, there were no TCGA normal samples with sufficient read count (N = 10) available or
theminimumPSI over all normal samples was lower than the smallest tumor sample PSI, we excluded the event. All remaining events
were noted as outliers in the respective cancer type.
t-SNE
Wehave generated t-SNE figures for every event type (exon-skip, alternative events and intron retention) aswell as for a list of concat-
enated events based on a matrix of sample by event matrix of percent spliced in values. All t-SNE figures have been produced using
the package sklearn (Pedregosa et al., 2011). The aforementioned matrix has been filtered to remove events which had more than
30% samples missing values. A value is missing, if we were unable to compute a stable PSI value, which was the case when we
had less than 10 spliced reads available in the denominator. Samples have been filtered if more than 10% of events had samples
missing. Remaining missing values have beenmean-imputed. Next, we performed a PCA based on a linear kernel of this data matrix.
The first 100 principal components have been used for the t-SNE generation. t-SNE with learning rate 500 and perplexity 50 have
been used for visualization throughout this work unless stated otherwise.
Differential Analysis of Splicing Events
The differential splicing analysis was run on all tumor types that had at least 50 tumor samples and 10 tissue-matched normal
samples available. For each tumor type independently, we randomly subsampled the available groups to 50 tumor and 10 normal
samples.We then usedSplAdder to perform a differential test (based on a generalized linear model) between the two groups, utilizing
the split-alignment counts acress the junctions of an event. To account for additional variability in the tumor samples, we repeated the
testing 9 times, each time on a different random subset. For each event, the final p value was recorded as the median of the 9 results.
If the same gene had more than one splicing event tested, we kept the one with the minimal p value. The results from all individual
tissues were then aggregated into a common ranking using Fisher’s method for meta-analysis.
Filtering of Events and Variants for Somatic trans-Association
As phenotypes we considered a total of 94,749 exon skipping, 30,755 alternative 50 and 48,365 alternative 30 events for all samples
that had a total of at least five reads across all junctions in the splicing event. We considered tumor sample population-level variant
calls that are confirmed by at least three somatic variant callers as high-quality somatic variants in at least two donors in the MC3
variant calls, including intronic regions. For each of these positions, we re-analyzed the tumor whole exome sequencing data in order
to determine the genotype in all samples. This strategy considered germline as well as somatic variants for the association analysis.
Therefore, we leveraged the occurrence of single nucleotide variants on the germline genome in conjunction with somatic single
nucleotide variants to determine functional effects of these variants.
Statistical Association of Genetic Variation and Alternative Splicing
A linear mixed model has been used (Lippert et al., 2014), accounting for population structure as a random effect and cancer type as
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effects to account for potential detection bias. All splicing event quantifications have been quantile normalized to match a standard
normal distribution. Depending on the amount of read support of individual splice events, we used up to 8,255 samples for the
QTL-analysis. More specifically, we required that the sum of reads across all junction for every sample and splice event are covered
by more or equal to 5 reads.
The splicing index is being used as a quantitative phenotype. In order to address some unwanted properties of this phenotype we
have performed an inverse normal transform on all PSI’s estimated by SplAdder. To avoid ties, we have added a small amount of
random pseudo-noise in the range of 105 to each estimate before transformation. Splicing events which exclusively exhibited
ties, have been removed from analysis. We also excluded phenotypes in which less than 10%of the samples had any valid estimates.
We applied a Bonferroni multiple testing correction on cis-associations and trans-associations separately accounting for the total
number of variants (cis-associations, p value < 6.19e-6) as well as the total number of events and variants tested (trans-associations,
p value < 3.55e-11).
In the resulting set of sQTL, we have removed all events which showed over-inflation for the variants tested (more than 20 variants
significantly associated). Further, we tested all variants for association with mutational load (Spearman Correlation) and removed all
variants showing any evidence of correlation (nominal p value < 0.01). Mutational load has been calculated as total number of SNV
based on MC3 calls from PanCanAtlas have been used (version 0.2.8 PUBLIC; Synapse ID: syn7834470).
Derivation of Splicing-Derived Peptides
Based on the splicing graphs, all intron-spanning polypeptides (encoding the translated amino acid sequence of a node pair) for a
subset of 63 TCGA cancer samples (including BRCA andOV) were derived. For each gene, we generated a foreground splicing graph
by collapsing the reference transcripts of each gene into a graph and augmenting it with patient-specific germline and somatic var-
iants as well as additional junction information from RNA-seq across the TCGA cohort as follows.
The polypeptides were obtained by seeding the splicing graph traversal at the first CDS of the canonical transcripts and then
following the splicing graph structure along any existing edges in read strand order. While traversing the graph, all possible
read-frame shifts that could exist while translating an exon/CDS were taken into account. We define an intron-spanning polypeptide
as the peptide generated by translating the pair of exons connected by the intron with respect to a certain reading-frame. The poly-
peptides were generated both for the reference DNA sequence and the personalized DNA sequences. Personalized DNA sequences
are comprised of three subsets obtained by introducing variants into the reference genome as follows: (i) the germline variants of a
particular donor only, (ii) the somatic variants of a particular donor only, and (iii) both the germline and the somatic variants. To obtain
background sequences, we generated polypeptides that result from translating canonical transcripts annotated in the GENCODE
reference annotation (version 19). Furthermore, we generate background peptides by using a splicing graph derived from GTEx
control tissue samples. For each donor, we also generate a personalized GTEx background set by introducing germline variants.
MHC-I Binding Predictions
MHC class I binding predictions were performed using NetMHC-4.0 (Andreatta and Nielsen, 2016). Donor HLA-I types originate from
a previous study on the same TCGA samples (Shukla et al., 2015) and were downloaded from the PanCanAtlas Jamboree server.
For each tumor sample, MHC-I binding affinity and corresponding ranks were determined for all 9-mers derived from background
and personalized protein sequences with respect to all donor HLA-I alleles supported by NetMHC-4.0. (For seven donors only three
HLA-I alleles were supported, for 17 donors all six were. Median number of supported alleles was 5.) For each 9-mer NetMHC-4.0
outputs a binding affinity rank per allele. This rank is based on a reference set of 400,000 random natural peptides. Peptides with a
predicted binding affinity rank of better than 2% are considered binders. NetMHC-4.0 was used as follows:
MHC-I Binding Prediction
netMHC -a <donor_allele_string> -l 9 -f <proteins.fasta>
Identification of Expressed Peptides
For each of the 63 TCGA tumor samples under consideration, we generated individual polypeptide databases comprising reference-
based and personalized versions of all sample-specific splicing-derived and reference annotation-derived protein sequences.
Personalized versions of the reference annotation-derived protein sequences were generated analogously to those of the
splicing-derived sequences.
OpenMS (Kohlbacher et al., 2007; Ro¨st et al., 2016) was used to identify polypeptides from a sample’s polypeptide database as
follows: In order to allow to control for false discovery rates, decoy sequences were added to the database. Subsequently, we used
MS-GF+ to search the corresponding CPTAC data set for tryptic sequences from the database. A false discovery rate of 5% on the
peptide-spectrum match level was used to filter the identified polypeptides. Any 9-mer contained in at least one of the identified
polypeptides is considered CPTAC-confirmed. The following OpenMS commands were used to perform the polypeptide
identification:
Add Decoy Sequences
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Search CPTAC Data Set
MSGFPlusAdapter -ini MSGF_iTRAQ.ini -in <cptac_spectra> -out <output.idXML> -database <decoy_db.fasta> -executable
<path_to_msgfplus> -java_memory 80000 -threads 6
The file MSGF_iTRAQ.ini is available at https://github.com/ratschlab/pancanatlas_code_public.
Control for False Discovery Rate
PeptideIndexer -in <msgf_output.idXML> -fasta <decoy_db.fasta> -out <pi_output.idXML> -allow_unmatched -enzyme:
specificity ’semi’
FalseDiscoveryRate -in <pi_output.idXML> -out <fd_output.idXML>
IDFilter -in <fd_output.idXML> -out <fdr_filtered.idXML> -score:pep 0.05
Alternative Splicing-Derived Neoepitope Candidates
Starting from a sample’s splicing-derived polypeptide sequences we extracted all intron-spanning peptides of length 9. Due to the
lack of normal RNA samples, tumor-specific splicing events cannot be accurately determined. In order to increase specificity,
we consider all splicing events observed in GTEx as normal and exclude all GTEx 9-mers (including personalized peptides) from
the list of alternative splicing-derived neoepitope candidates. Furthermore, all 9-mers also observed in the reference genome or
the personalized reference genome, i.e., the reference genome after introduction of the respective donor’s germline variants and/or
the somatic variants, were removed from the list. Furthermore, in order to increase specificity, we only considered 9-mers derived
from EEJs also contained in the splicing graph generated on the new RNA-seq alignments (strategy 2).
SNV-Derived Neoepitope Candidates
Starting from a donor’s personalized reference genome representing either somatic variants only or both germline and somatic
variants, all peptides of length 9 containing a somatic variant are extracted. All 9-mers also found in the reference genome or in
the personalized genome containing germline variants only are removed from this list. Moreover, analogous to the identification of
alternative splicing-derived neoepitope candidates, all GTEx 9-mers (including personalized peptides) are excluded.
Estimation of RNA Expression of 9-mer Peptides
RNA expression of 9-mers overall was determined by using the average RNA expression of the corresponding exon fragment as a
proxy. For SNV-derived 9-mers this expression was multiplied by the respective variant allele frequency. We estimated the RNA
expression of neojunction derived 9-mers by library size-normalizing the read counts confirming the respective junction.
Re-analysis on Representative Sample Subset
As a means to account for various sampling differences in the TCGA RNA-seq data set, we generated a representative sub-cohort
with a reduced variability to repeat some of the key analysis. From the set of whitelisted samples passing our initial QC, we selected
10 tumor and 10 normal samples for all cancer types that had at least 10 tumor and 10 normal samples available. We pre-processed
the fastq files of these samples and randomly subsampled each sample to contain 48,000,000 reads. All reads exceeding 50nt were
trimmed down to 50nt. For alignment, we used strategy 2 as described above. All downstream analyses were analog as
described above.
DATA AND SOFTWARE AVAILABILITY
Supplementary data accompanying this manuscript is available at the Genomic Data Commons (GDC) of the National Cancer
Institute under the following URL: https://gdc.cancer.gov/about-data/publications/PanCanAtlas-Splicing-2018.
Research code that was used to implement methods described above along with further descriptions is publicly available on
GitHub under the following address: https://github.com/ratschlab/pancanatlas_code_public.e6 Cancer Cell 34, 211–224.e1–e6, August 13, 2018
